摘要
肠易激综合征(IBS)是临床上常见的功能性胃肠道疾病,患病率逐年升高。便秘型肠易激综合征(IBS-C)是常见的一种IBS,其发生可能与肠道的异常过度收缩、内脏神经的高敏感和脑-肠轴功能紊乱有关。目前,IBS-C的治疗对患者的生活质量改善有限。利那洛肽是一种含有14个氨基酸的多肽,是国内第一个上市的口服肠上皮细胞鸟苷酸环化酶C(GC-C)激动剂,作用机制不同于现有IBS-C治疗药物,可有效改善患者的症状。此外,利那洛肽的降解产物主要分布在胃肠道,故很少引起肾脏、肝脏损伤,药效不受肝肾功能影响。已有多项随机、双盲临床试验结果表明,利那洛肽治疗可明显改善IBS-C患者的腹痛、腹部不适和便秘等症状,提高患者生活质量。
引文
[1] FORD A,MOAYYEDI P,LACY B,et al.American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation[J].Am J Gastroenterol,2014,109(Suppl 1):S2.
[2] TALLEY N,HOLTMANN G.Irritable bowel syndrome and functional dyspepsia:what can epidemiology tell us about etiology?[J].Expert Rev Gastroenterol Hepatol,2018,12(7):633.
[3] DROSSMAN D A,HASLER W L.Rome IV-functional gi disorders:disorders of gut-brain interaction[J].Gastroenterology,2016,150(6):1257.
[4] ZHANG F,XIANG W,LI C Y,et al.Economic burden of irritable bowel syndrome in China[J].World J Gastroenterol,2016,22(47):10450.
[5] 熊理守,陈旻湖,陈惠新,等.广东省社区人群肠易激综合征的流行病学研究[J].中华医学杂志,2004,84(4):278.
[6] CHASSANY O,MARQUIS P,SCHERRER B,et al.Validation of a specific quality of life questionnaire for functional digestive disorders[J].Gut,1999,44(4):527.
[7] MEARIN F,CIRIZA C,MINGUEZ M,et al.Clinical Practice Guideline:Irritable bowel syndrome with constipation and functional constipation in the adult[J].Rev Esp Enferm Dig,2016,108(6):332.
[8] 中华医学会消化病学分会胃肠功能性疾病协作组,中华医学会消化病学分会胃肠动力学组.中国肠易激综合征专家共识意见(2015年,上海)[J].中华消化杂志,2016,36(5):299.
[9] SMITH H W,GYLES C L.The relationship between two apparently different enterotoxins produced by enteropathogenic strains of Escherichia coli of porcine origin[J].J Med Microbiol,1970,3(3):387.
[10] HASEGAWA M,SHIMONISHI Y.Recognition and signal transduction mechanism of Escherichia coli heat-stable enterotoxin and its receptor,guanylate cyclase C[J].J Pept Res,2005,65(2):261.
[11] KUHN M.Molecular physiology of membrane guanylyl cyclase receptors[J].Physiol Rev,2016,96(2):751.
[12] CURRIE M,KURTZ C,MAHAJAN-MIKLOS S,et al.Effects of single dose administration of MD-1100 on safety,tolerability,exposure,and stool consistency in healthy subjects[EB/OL].(2005-01-01)[2019-06-14].https://journals.lww.com/ajg/Fulltext/2005/09001/Effects_of_Single_Dose_Administration_of_MD_1100.894.aspx.
[13] FDA.LINZESS (linaclotide) capsules,for oral use Initial U.S.Approval:2012[EB/OL].[2019-06-14].https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202811s000lbl.pdf.
[14] Constella 290 micrograms hard capsules[EB/OL].[2019-06-14].https://www.medicines.org.uk/emc/product/2041.
[15] 国家药品监督管理局.进口药品查询[EB/OL].[2019-06-14].http://qy1.sfda.gov.cn/datasearchcnda/face3/base.jsp?tableId=36&tableName=TABLE36&title=%E8%BF%9B%E5%8F%A3%E8%8D%AF%E5%93%81&bcId=152904858822343032639340277073.
[16] RAO S,LEMBO A J,SHIFF S J,et al.A 12-week,randomized,controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation[J].Am J Gastroenterol,2012,107(11):1714.
[17] LEMBO A J,SCHNEIER H A,SHIFF S J,et al.Two randomized trials of linaclotide for chronic constipation[J].N Engl J Med,2011,365(6):527.
[18] CHEY W D,LEMBO A J,LAVINS B J,et al.Linaclotide for irritable bowel syndrome with constipation:a 26-week,randomized,double-blind,placebo-controlled trial to evaluate efficacy and safety[J].Am J Gastroenterol,2012,107(11):1702.
[19] JOHNSTON J M,KURTZ C B,MACDOUGALL J E,et al.Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation[J].Gastroenterology,2010,139(6):1877.
[20] YIANNAKOU Y,AGRAWAL A,ALLEN P B,et al.UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation[J].Therap Adv Gastroenterol,2018,11:1756284818798791.
[21] ANDRESEN V,MIEHLKE S,BECK E,et al.Efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in a realworld setting - results from a German noninterventional study[J].Z Gastroenterol,2018,56(7):738.
[22] BHARUCHA A E,WALDMAN S A.Taking a lesson from microbial diarrheagenesis in the management of chronic constipation[J].Gastroenterology,2010,138(3):813.
[23] WALDMAN S A,CAMILLERI M.Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders[J].Gut,2018,67(8):1543.
[24] GONGORA-BENITEZ M,TULLA-PUCHE J,ALBERICIO F.Constella(EU)-Linzess(USA):the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs[J].Future Med Chem,2013,5(3):291.
[25] WALDMAN S A,O'HANLEY P.Influence of a glycine or proline substitution on the functional properties of a 14-amino-acid analog of Escherichia coli heat-stable enterotoxin[J].Infect Immun,1989,57(8):2420.
[26] BUSBY R W,BRYANT A P,BARTOLINI W P,et al.Linaclotide,through activation of guanylate cyclase C,acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit[J].Eur J Pharmacol,2010,649(1-3):328.
[27] BASSOTTI G,USAI-SATTA P,BELLINI M.Linaclotide for the treatment of chronic constipation[J].Expert Opin Pharmacother,2018,19(11):1261.
[28] 刘雪莲,杨见权,潘昭杰.利那洛肽治疗便秘型肠易激综合征的Meta分析[J].中国新药与临床杂志,2013,32 (8):650.
[29] NOMURA K,YOSHIDA M.Assessment of the learning curve for microendoscopic decompression surgery for lumbar spinal canal stenosis through an analysis of 480 cases involving a single surgeon[J].Global Spine J,2017,7(1):54.
[30] SCHLOSSMANN J,FEIL R,HOFMANN F.Insights into cGMP signalling derived from cGMP kinase knockout mice[J].Front Biosci,2005,10:1279.
[31] GIANNELLA R A,MANN E A.E.coli heat-stable enterotoxin and guanylyl cyclase C:new functions and unsuspected actions[J].Trans Am Clin Climatol Assoc,2003,114:67.
[32] VAANDRAGER A,SMOLENSKI A,TILLY B,et al.Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl- channel activation[J].Proc Natl Acad Sci USA,1998,95(4):1466.
[33] TCHERNYCHEV B,GE P,KESSLER M,et al.MRP4 modulation of the guanylate cyclase-C/cGMP pathway:effects on linaclotide-induced electrolyte secretion and cGMP efflux[J].J Pharmacol Exp Ther,2015,355(1):48.
[34] JOHNSTON J,KURTZ C,DROSSMAN D,et al.Pilot study on the effect of linaclotide in patients with chronic constipation[J].Am J Gastroenterol,2009,104(1):125.
[35] KANAZAWA M,PALSSON O,THIWAN S,et al.Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits[J].Am J Gastroenterol,2008,103(10):2550.
[36] van Der VEEK P,van ROOD Y,MASCLEE A.Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome[J].Clin Gastroenterol Hepatol,2008,6(3):321.
[37] FARZAEI M,BAHRAMSOLTANI R,ABDOLLAHI M,et al.The role of visceral hypersensitivity in irritable bowel syndrome:pharmacological targets and novel treatments[J].J Neurogastroenterol Motil,2016,22(4):558.
[38] AZPIROZ F,BOUIN M,CAMILLERI M,et al.Mechanisms of hypersensitivity in IBS and functional disorders[J].Neurogastroenterol Motil,2007,19(Suppl 1):62.
[39] 康明祥,贾红.肠易激综合征内脏高敏感性机制的研究进展[J].世界华人消化杂志,2008,16(14):1554.
[40] SIMR N M,T RNBLOM H,PALSSON O S,et al.Management of the multiple symptoms of irritable bowel syndrome[J].Lancet Gastroenterol Hepatol,2017,2(2):112.
[41] BHARUCHA A E,LINDEN D R.Linaclotide - a secretagogue and antihyperalgesic agent - what next?[J].Neurogastroenterol Motil,2010,22(3):227.
[42] RITTER C,JEDLITSCHKY G,MEYER Z U,SCHWABEDISSEN H,et al.Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5)[J].Drug Metab Rev,2005,37(1):253.
[43] ZIMMERMANN C,GUTMANN H,HRUZ P,et al.Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract[J].Drug Metab Dispos,2005,33(2):219.
[44] SAGER G.Cyclic GMP transporters[J].Neurochem Int,2004,45(6):865.
[45] CASTRO J,HARRINGTON A M,HUGHES P A,et al.Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3’,5’-monophosphate[J].Gastroenterology,2013,145(6):1334.
[46] CERVETTO C,MAURA G,MARCOLI M.Inhibition of presynaptic release-facilitatory kainate autoreceptors by extracellular cyclic GMP[J].J Pharmacol Exp Ther,2010,332(1):210.
[47] EUTAMENE H,BRADESI S,LARAUCHE M,et al.Guanylate cyclase C‐mediated antinociceptive effects of linaclotide in rodent models of visceral pain[J].Neurogastroenterology & Motility,2010,22(3):312.
[48] LAYER P,STANGHELLINI V.Linaclotide for the management of irritable bowel syndrome with constipation[J].Aliment Pharmacol Ther,2014,39(4):371.
[49] 李冬青,李莹.离子型谷氨酸受体在疼痛中的作用机制探讨[J].中国药物经济学,2013,5:395.
[50] POULOPOULOU C,NOWAK L M.Extracellular 3',5' cyclic guanosine monophosphate inhibits kainate-activated responses in cultured mouse cerebellar neurons[J].J Pharmacol Exp Ther,1998,286(1):99.
[51] LEE N,WALD A.Linaclotide:evidence for its potential use in irritable bowel syndrome and chronic constipation[J].Core Evid,2012,7:39.
[52] BUSBY R W,KESSLER M M,BARTOLINI W P,et al.Pharmacologic properties,metabolism,and disposition of linaclotide,a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation[J].J Pharmacol Exp Ther,2013,344(1):196.
[53] YANG Y,FANG J,GUO X,et al.Linaclotide in irritable bowel syndrome with constipation:A Phase 3 randomized trial in China and other regions[J].J Gastroenterol Hepatol,2018,33(5):980.
[54] SCHNEIER H,SHIFF S,HAO X,et al.PTH-136 two years on linaclotide:tolerability and treatment satisfaction in patients with irritable bowel syndrome with constipation with and without diarrhoea[J].Gut,2017,66:A274.
[55]GRUNDR L,CASTRO J,MADDERN J,et al.Chronic colonic administration of the guanylate cyclase-C agonist linaclotide attenuates colitis induced bladder afferent hyperactivity [EB/OL].[2019-06-14].https://ddw.scientificposters.com/epsAbstractDDW.cfm?id=5.
[56] CASTRO J,HARRINTRON A,MADDERN J,et al.Chronic intracolonic administration of linaclotide inhibits nociceptive signaling in a mouse model of chronic visceral hypersensitivityy [EB/OL].[2019-06-14].https://ddw.scientificposters.com/epsAbstractDDW.cfm?id=3.
